WO2023089375 - THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
National phase entry is expected:
Publication Number
WO/2023/089375
Publication Date
25.05.2023
International Application No.
PCT/IB2022/000692
International Filing Date
21.11.2022
Title **
[English]
THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
[French]
COMPOSÉS THÉRAPEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
Applicants **
LIGATURE THERAPEUTICS PTE, LTD.
30 Cecil Street #19-08
Prudential Tower
Singapore 049712, SG
Inventors
SRINIVASAN, Rajavel
#10-121, Blk 177 Yung Sheng Road
Singapore 610177, SG
HUNG, Wei
146 Cactus Road
Singapore 809651, SG
Priority Data
63/281,984
22.11.2021
US
17/532,698
22.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IPOS
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1823 | |
| EPO | Filing, Examination | 10519 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 4710 |
Total: 18254 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
There are provided new inhibitors of MDM2. Also provided are methods of synthesizing the agents, pharmaceutical formulations including the agents, and methods of using the agents to treat, ameliorate or cure diseases characterized by MDM2 over-expression or malfunction.[French]
L'invention concerne de nouveaux inhibiteurs de MDM2. L'invention concerne également des procédés de synthèse des agents, des formulations pharmaceutiques comprenant les agents, et des procédés d'utilisation des agents pour traiter, atténuer ou guérir des maladies caractérisées par une surexpression ou un dysfonctionnement de MDM2.